Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gustafson

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
International Journal of Radiation Oncology, Biology, Physics|January 4, 2011
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapyAlvaro A Martinez, Jose Gonzalez, Hong Ye, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation studyAsif Harsolia, Carlos Vargas, Di Yan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancerRazvan M Galalae, Alvaro Martinez, Tim Mate, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancerAlvaro A Martinez, Gary Gustafson, José Gonzalez, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 11, 2020
Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancerJacob S Parzen, Hong Ye, Gary Gustafson, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
International Journal of Radiation Oncology, Biology, Physics|January 4, 2011
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapyAlvaro A Martinez, Jose Gonzalez, Hong Ye, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation studyAsif Harsolia, Carlos Vargas, Di Yan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancerRazvan M Galalae, Alvaro Martinez, Tim Mate, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancerAlvaro A Martinez, Gary Gustafson, José Gonzalez, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 11, 2020
Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancerJacob S Parzen, Hong Ye, Gary Gustafson, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Pageof 3